Human Trials Begin on Antibody Treatment for COVID-19
A small trial of 32 patients is evaluating a new antibody drug developed specifically to fight the novel coronavirus. The trial will determine what, if any, side effects arise. Discovered by Vancouver-based AbCellera and developed by Eli Lilly in Indianapolis, the drug is designed to decrease the levels of SARS-CoV-2 in the body, enabling patients to recover. There is also hope that the drug may be useful as a preventive agent. Many other antibody drugs are also currently in development. It is hoped that more than one effective drug will be created, and that millions of doses will be available before the end of 2020. Read more here.
